Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

"Virtual patch clamp analysis" for predicting the functional significance of pathogenic variants in sodium channels.

Epilepsy research·2022

Same author

Computerized extraction of the time dimension in histopathological sections.

Applied optics·2010

Same author

Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.

Cytotherapy·2009

Same author

Mechanisms for acquired activated protein C resistance in cancer patients.

Journal of thrombosis and haemostasis : JTH·2005

Same author

Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein.

International journal of cancer·2001

Same author

K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.

International journal of cancer·2001

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Novel antibodies as anticancer agents.

I Zafir-Lavie¹, Y Michaeli, Y Reiter

¹Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.

|May 29, 2007

Summary

Monoclonal antibodies, developed through advanced recombinant DNA and protein engineering, are emerging as targeted cancer therapies. These guided missiles precisely identify and attack cancer cells, offering a new generation of anticancer agents.

Area of Science:

Immunologic research
Biotechnology
Cancer biology

Background:

Antibodies have evolved from 'magic bullets' to sophisticated 'guided missiles' in cancer therapy.
Advances in antigen screening and protein engineering enable the development of specific anticancer remedies.
Understanding cancer biology and utilizing recombinant DNA technology allows for the rational design of novel pharmaceuticals.

Purpose of the Study:

To review novel antibodies and antibody-based approaches for cancer treatment.
To highlight the evolution of antibody technology in oncology.
To discuss the potential of monoclonal antibodies as a new generation of anticancer agents.

Main Methods:

Review of recent literature on antibody development and cancer research.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Analysis of antigen screening and protein engineering techniques.

Examination of recombinant DNA strategies in antibody generation.

Main Results:

Monoclonal antibodies and their fragments are being developed as targeted cancer therapies.
Novel techniques allow for the distinction between malignant and normal cells.
Antibodies offer high specificity and affinity for targeting cancer cells.

Conclusions:

Antibody-based therapies represent a significant advancement in oncology.
The plasticity of antibody structure allows for targeted drug delivery.
Ongoing research promises a new era of antibody-driven anticancer agents.